Metastatic Triple Negative Breast Cancer: Overcoming Challenges in Diagnosis Treatment and Management : Episode 5
Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC
Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.
EP: 1.Background on Metastatic Triple Negative Breast Cancer
EP: 2.Initial Treatment Options for Metastatic TNBC
EP: 3.Second-Line Therapy for Metastatic TNBC
EP: 4.ASCENT Study: Impact of Sacituzumab Govitecan on Metastatic TNBC
Now Viewing
EP: 5.Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC
EP: 6.Overcoming Barriers to Treatment Access and Reimbursement
Related Videos
Related Content
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024Podcast
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen
